talquetamab

Talquetamab is a first-in-class **GPRC5D × CD3 T-cell-redirecting bispecific monoclonal antibody** developed by Johnson & Johnson for **relapsed or refractory multiple myeloma**. It binds **G protein-coupled receptor class C group 5 member D (GPRC5D)** on myeloma cells and **CD3** on T cells, thereby recruiting and activating T cells to kill GPRC5D-expressing plasma cells. The drug is administered **subcutaneously** with step-up dosing to mitigate cytokine release syndrome. It is marketed in the United States as **Talvey** for adults with heavily pretreated relapsed or refractory multiple myeloma, and has also been studied in combinations such as talquetamab plus pomalidomide and as bridging therapy before CAR-T treatment. Its toxicity profile is notable for **cytokine release syndrome, ICANS/neurotoxicity, oral toxicity including dysgeusia and xerostomia, skin and nail toxicities, weight loss, cytopenias, and infections**.

Brand names

Talvey

Other names

talquetamab-tgvs